Filana Therapeutics, Inc. (FLNA)
0.8201
-0.01
(-0.99%)
USD |
NASDAQ |
Sep 04, 16:00
0.8183
0.00 (0.00%)
After-Hours: 20:00
Filana Therapeutics Research and Development Expense (Quarterly) : 3.303M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.303M |
| March 31, 2026 | 4.544M |
| December 31, 2025 | 3.853M |
| September 30, 2025 | 3.955M |
| June 30, 2025 | 5.116M |
| March 31, 2025 | 13.67M |
| December 31, 2024 | 20.53M |
| September 30, 2024 | 17.68M |
| June 30, 2024 | 15.20M |
| March 31, 2024 | 16.23M |
| December 31, 2023 | 18.73M |
| September 30, 2023 | 23.60M |
| June 30, 2023 | 24.97M |
| March 31, 2023 | 22.12M |
| December 31, 2022 | 17.65M |
| September 30, 2022 | 18.93M |
| June 30, 2022 | 17.35M |
| March 31, 2022 | 15.01M |
| December 31, 2021 | 10.79M |
| September 30, 2021 | 10.03M |
| June 30, 2021 | 4.787M |
| March 31, 2021 | 3.105M |
| December 31, 2020 | 2.343M |
| September 30, 2020 | 1.374M |
| June 30, 2020 | 1.688M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.886M |
| December 31, 2019 | 1.692M |
| September 30, 2019 | 1.486M |
| June 30, 2019 | 1.746M |
| March 31, 2019 | 0.574M |
| December 31, 2018 | 0.002M |
| September 30, 2018 | 0.436M |
| June 30, 2018 | 1.463M |
| March 31, 2018 | 1.068M |
| December 31, 2017 | 1.544M |
| September 30, 2017 | 1.619M |
| June 30, 2017 | 3.063M |
| March 31, 2017 | 1.388M |
| December 31, 2016 | 1.335M |
| September 30, 2016 | 2.657M |
| June 30, 2016 | 1.589M |
| March 31, 2016 | 3.595M |
| December 31, 2015 | 3.62M |
| September 30, 2015 | 2.356M |
| June 30, 2015 | 1.986M |
| March 31, 2015 | 1.138M |
| December 31, 2014 | 1.108M |
| September 30, 2014 | 2.116M |
| June 30, 2014 | 1.935M |
| March 31, 2014 | 2.147M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| CorMedix, Inc. | 6.684M |
| Eloxx Pharmaceuticals, Inc. | 2.84M |
| Cannabis Global, Inc. | -- |
| Breakthrough Chemistry, Inc. | 0.0041M |
| BioStem Technologies, Inc. | 0.7336M |